Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Pronova BioPharma ASA : Omacor and Zodin placed on negative reimbursement list in Greece


Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-01-11 07:54:29 -

Lysaker, Norway, 11 January 2013: Pronova BioPharma (OSE: PRON.OL) has been
informed that Omacor and Zodin have been placed on a negative reimbursement list
in Greece as part of cost containment measures that is currently being
implemented. The negative reimbursement list includes several hundred
pharmaceutical products and was put in place in December.

Pronova and its partners in Greece, Abbott Laboratories and Grupo Ferrer, have
appealed the decision in order to secure continued good access to Omacor and
Zodin for Greek patients.

Greece is among the 8 largest markets for Pronova, and  represents around 4
percent of Pronova's total sales. Pronova has sales to 61 countries.

Pronova BioPharma ASA
Hamed Brodersen,
VP Investor Relations and Communications
Tel: +47 40 46 81 10


This information is subject of the disclosure requirements pursuant to section
5-12 of 
the Norwegian Securities Trading Act. This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Pronova BioPharma ASA via Thomson Reuters ONE [HUG#1669759]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser